Bastide le Confort Medical S.A.

Bastide le Confort Medical is a holding company. Through its subsidiaries, Co. is engaged in the home health care industry. Co. retails and rents medical equipment and provides medical services. Products include breathing apparatus, orthopedic shoes, walking aids and wheelchairs, home appliances and furniture adapted to the needs of the lesser able, with the recent addition of equipment related to perfusion and nutrition. Co. operates through a number of outlets concentrated mainly in the South of France, offering advice and information to customers along with the provision and maintenance of medical equipment.
  • TickerBLC
  • ISINFR0000035370
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Christophe-Raphaël Ganet

Bastide : H1 2018-19 results: good level of margins, slight disappointment on cash – Guidance for the operating margin look cautious - Debt under control

>A good level of operating margin at 8.6% (vs 7.7% a year earlier) - H1 underlying operating profit was up 37.7%, to € 14.3m for net profit growth of “only” 22% to € 4.4m, impacted by i/ a number of non-recurring charges and an accounting adjustment for fair value for price supplements representing € 0.8m due to, amongst other things, an outperformance at Sphère Santé, ii/ a net loss of € 1.2m (the cancellation of a digitised patient management project, which is curre...

Christophe-Raphaël Ganet

Bastide : Résultat S1 2018/19 : bons niveaux de marge, légère déception sur le cash – La guidance de MOP apparaît prudente - Dette sous contrainte

>Bon niveau de MOP à 8,6% (contre 7,7% 1 an plus tôt) - Le ROC S1 affiche une hausse de 37,7%, à 14,3 M€ et le RN « que » de 22% à 4,4 M€ impacté par i/ diverses charges non récurrentes et un ajustement comptable de la juste valeur des compléments de prix pour 0,8 M€, en raison, entre autres, d’une surperformance de Sphère Santé, ii/ une perte nette de 1,2 M€ (abandon d’un projet de gestion informatisée de patients, aujourd’hui non stratégique). L’endettement net ress...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 03/14/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 14/03/2019

...

Christophe-Raphaël Ganet

Bastide : Q2 sales: +20.1% of which +7.3% organic: good in services, still difficult in home medical care– two small acquisitions

>Q2 sales (€ 86.4m) in line overall, but contrasting performance from various business lines (deterioration in home medical care) - Bastide has reported Q2 sales of € 86.4m, up 20.1%, of which +7.3% organic, giving q-o-q growth after 6.4% in Q1, in line with our forecasts (€ 87.3m). The H1 sales came in at € 165.8m (+24.0% of which +6.9% organic). For the first half and by activity:Home medical care (48% of the H1 sales) came to € 79.4m, i.e. +2.0% of which +2.7%...

Christophe-Raphaël Ganet

Bastide : H1 2018-19 results: good level of margins, slight disappointment on cash – Guidance for the operating margin look cautious - Debt under control

>A good level of operating margin at 8.6% (vs 7.7% a year earlier) - H1 underlying operating profit was up 37.7%, to € 14.3m for net profit growth of “only” 22% to € 4.4m, impacted by i/ a number of non-recurring charges and an accounting adjustment for fair value for price supplements representing € 0.8m due to, amongst other things, an outperformance at Sphère Santé, ii/ a net loss of € 1.2m (the cancellation of a digitised patient management project, which is curre...

Christophe-Raphaël Ganet

Bastide : Résultat S1 2018/19 : bons niveaux de marge, légère déception sur le cash – La guidance de MOP apparaît prudente - Dette sous contrainte

>Bon niveau de MOP à 8,6% (contre 7,7% 1 an plus tôt) - Le ROC S1 affiche une hausse de 37,7%, à 14,3 M€ et le RN « que » de 22% à 4,4 M€ impacté par i/ diverses charges non récurrentes et un ajustement comptable de la juste valeur des compléments de prix pour 0,8 M€, en raison, entre autres, d’une surperformance de Sphère Santé, ii/ une perte nette de 1,2 M€ (abandon d’un projet de gestion informatisée de patients, aujourd’hui non stratégique). L’endettement net ress...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 03/14/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 14/03/2019

...

Christophe-Raphaël Ganet

Bastide : Q2 sales: +20.1% of which +7.3% organic: good in services, still difficult in home medical care– two small acquisitions

>Q2 sales (€ 86.4m) in line overall, but contrasting performance from various business lines (deterioration in home medical care) - Bastide has reported Q2 sales of € 86.4m, up 20.1%, of which +7.3% organic, giving q-o-q growth after 6.4% in Q1, in line with our forecasts (€ 87.3m). The H1 sales came in at € 165.8m (+24.0% of which +6.9% organic). For the first half and by activity:Home medical care (48% of the H1 sales) came to € 79.4m, i.e. +2.0% of which +2.7%...

1 director bought

A director at Bastide Le Confort Medical bought 29,000 shares at 34.500EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The...

Alain William ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas David
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 02/07/2019

...

Alain William ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas David
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 07/02/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Jeremy Garnier
  • Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 01/10/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Jeremy Garnier
  • Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 10/01/2019

...

Christophe-Raphaël Ganet ...
  • Emmanuel Matot

ODDO BHF Small & MIDCAP MORNING NEWS - 12/21/2018

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Bastide Le Confort Médical - 03 Décembre 2018

Lors du dernier exercice, l’ensemble de l’équipe dirigeante, Directeur Général et Directeurs Généraux, a démissionné de leurs mandats sociaux. Suite à cela le Président du conseil, Guy Bastide, a repris les fonctions de direction, devenant ainsi Président Directeur Général de la société. Nous alertons, encore une fois, les actionnaires concernant la manque de transparence de la société dont elle fait preuve sur de nombreux éléments de son document de référence : tant concernant les conventions réglementées, que concernant sa politique de rémunération. Enfin il est proposé aux actionnaires de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch